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Abstract
Retroviral insertional mutagenesis provides an effective forward genetic method for identifying genes involved in essential
cellular pathways. A Chinese hamster ovary cell line mutant resistant to several bacterial ADP-ribosylating was obtained by
this approach. The toxins used catalyze ADP-ribosylation of eukaryotic elongation factor 2 (eEF-2), block protein synthesis,
and cause cell death. Strikingly, in the CHO PR328 mutant cells, the eEF-2 substrate of these ADP-ribosylating toxins was
found to be modified, but the cells remained viable. A systematic study of these cells revealed the presence of a structural
mutation in one allele of the eEF-2 gene. This mutation, Gly717Arg, is close to His715, the residue that is modified to
become diphthamide. This Arg substitution prevents diphthamide biosynthesis at His715, rendering the mutated eEF-2
non-responsive to ADP-ribosylating toxins, while having no apparent effect on protein synthesis. Thus, CHO PR328 cells are
heterozygous, having wild type and mutant eEF-2 alleles, with the latter allowing the cells to survive even in the presence of
ADP-ribosylating toxins. Here, we report the comprehensive characterization of these cells.
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Introduction
Diphthamide is a post-translationally modified histidine residue
found exclusively in eukaryotic translation elongation factor 2
(eEF-2) [1–3]. Cellular eEF-2 plays an essential role in translation
by mediating the movement of the transfer-RNA bound nascent
polypeptide chain between sites on the ribosome after addition of
each amino acid [4]. The diphthamide side chain is the target of
several potent bacterial toxins, specifically diphtheria toxin (DT),
Pseudomonas exotoxin A (ETA), cholix toxin of Vibrio cholerae, and
FP59, an anthrax toxin-derived fusion protein extensively used in
this laboratory [5–9]. These toxins exert their toxic effect by
catalyzing transfer of the ADP-ribose portion of NAD to
diphthamide, a modification that inactivates eEF-2 and leads to
cell death [5]. The biosynthesis of diphthamide is complex,
requiring at least five proteins to catalyze three steps in
construction of this post-translational modification of His715 in
eEF-2 [10]. This modification and the five biosynthetic proteins
are conserved in all eukaryotes, pointing to an important but still
elusive role for diphthamide in normal physiology.
DT and ETA were the first two ADP-ribosylating toxins
identified and biochemically characterized [11,12]. DT is
produced as a single polypeptide that requires cleavage into two
fragments. Fragment A contains the catalytic domain whereas
fragment B contains the receptor-binding domain and a region
involved in membrane translocation. DT binds to a specific
receptor, the heparin-binding epidermal growth factor-like
precursor, enters into the cytosol by receptor-mediated endocyto-
sis, and translocates from acidified endosomes to the cytosol,
where it inactivates eEF-2 [7,11]. On the other hand, ETA is a
single polypeptide chain which has an amino-terminal receptor-
binding domain, a central membrane translocation domain and a
carboxyl-terminal catalytic domain [12,13]. ETA uses the low-
density lipoprotein receptor-related protein (LRP1) to enter cells
by endocytosis, and then trafficks by a retrograde route to the
endoplasmic reticulum to eventually reach the cytosol [13]. The
newly discovered cholix toxin of Vibrio cholerae also has the same
enzymatic activity, but little is known about its receptor and the
mechanism by which it reaches the cytosol [8].
This laboratory has exploited the potency of the ADP-
ribosylating toxins as a tool in characterizing the anthrax toxins.
Thus, we routinely use a chimeric toxin termed fusion protein 59
(FP59), which utilizes the anthrax toxin receptor and translocation
mechanism to deliver the ADP-ribosylating domain of ETA to the
cytosol of cells [6]. Anthrax toxin is comprised of three proteins,
protective antigen (PA), lethal factor (LF) and edema factor (EF)
[14]. The combination of PA and LF is termed lethal toxin (LT).
PA binds to either the tumor endothelium marker 8 (TEM8) or
capillary morphogenesis gene product 2 (CMG2) proteins on the
cell surface and causes the endocytosis and trafficking of LF and
EF to the cytosol of host cells [14]. The toxicity of LT is due to the
catalytic activity of LF, a protease which cleaves several MAP
kinase kinases [15]. In FP59, the amino-terminal 254 residues of
lethal factor, which constitutes the domain responsible for binding
to PA, are fused with the catalytic domain of ETA [6,16]. FP59
administered with PA is toxic to mammalian cells due to delivery
of FP59 to the cytosol. The receptors for PA are widely distributed,
making the PA + FP59 combination lethal to almost all cell types
tested. Based on classical studies with DT [17], it is expected that a
single molecule of these toxins can inactivate a cell’s entire supply
of eEF-2 within hours, bringing protein synthesis to a halt and
leading to cell death.
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receptor, retroviral insertional mutagenesis was performed with
CHO WTP4 (i.e., parental) cells, and clones were selected for
resistance to PA + FP59 [18]. Mutants were initially classified into
two groups - one group having defects in toxin uptake and another
group that were cross-resistant to other ADP-ribosylating toxins
[18]. The uptake mutants included CHO PR230, which was
shown to lack a functional toxin receptor [19]. Most of the latter,
cross-resistant mutants were found to have defects in the synthesis
of diphthamide, the unique modified His residue in eEF-2 that is
the target of ADP-ribosylation. One mutant cell line from the
second group, CHO PR328, showed less sensitivity to all the ADP-
ribosylating toxins, DT, ETA, and FP59. However, the CHO
PR328 mutant cells were found to differ from other mutants in
that the eEF-2 of these cells were sensitive to toxin-induced ADP-
ribosylation. We performed a systematic study to characterize
these cells, as reported in the present work.
Results
Toxin Induced Cytotoxicity and ADP-Ribosylation of
eEF-2 in CHO PR328 Cells
CHO PR328 cells were obtained from parental CHO WTP4
cells following selection with a combination of anthrax PA and
fusion protein FP59 [18]. In cytotoxicity assays, .50% of CHO
PR328 cells survived even very high concentrations of the ADP-
ribosylating toxins DT, ETA and fusion toxin PA + FP59, while
parental CHO WTP4 cells were highly sensitive to these toxins
(Fig. 1a).
To determine whether the CHO PR328 cells contain eEF-2
that can be ADP-ribosylated, the cells were treated with DT or
ETA for 1 h and then cell lysates were separated on native PAGE
followed by western blotting with anti-eEF-2 antibodies. We
previously showed that the added negative charge of ADP-ribose
causes ADP-ribosylated eEF-2 to migrate faster than unmodified
Figure 1. Toxin induced cytotoxicity and ADP-ribosylation of eEF-2. (A) CHO PR328 and their parental cells, CHO WTP4, were incubated with
the indicated concentrations of toxins (in case of toxicity to FP59, PA was also added at a fixed concentration of 500 ng/ml). Cell viability was
assessed at 48 h by the MTT assay. The A540 values obtained for cells that received no toxin were considered as 100 % and used to calculate the
percent viability of other data points. (B) Cells were treated with 100 ng/ml of diphtheria toxin (DT) or Pseudomonas exotoxin A (ETA) for 4 h and the
cell lysate was tested for the presence of ADP-ribosylated eEF-2. Equal amount of cell lysate was subjected to native PAGE followed by western
blotting with anti-eEF-2 antibodies. As discussed in ‘Results’, these antibodies react more strongly with the ADP-ribosylated form than with the
unmodified EF-2. W and P symbolize CHO WTP4 and CHO PR328 cells respectively. Arrow indicates the ADP-ribosylated eEF-2.
doi:10.1371/journal.pone.0009078.g001
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PR328 cells was ADP-ribosylated in a manner similar to that in
the parental cells (Fig. 1b). This result was surprising, since the
modified eEF-2 cannot function in protein synthesis, yet these cells
survived. This analysis also seemed to show that there was less
ADP-ribosylated eEF-2 in the CHO PR328 lysates than in the
parental cell lysates. However, as we noted previously [10], the
antibody used here reacts more strongly to the modified eEF-2
than to the native protein (compare the ‘‘W’’ bands in control vs.
toxin treated lanes), so that the relative amounts of the two forms
cannot be estimated from images like that in Fig. 1b.
Validation of Toxin Internalization in CHO PR328 Cells
While the data in Fig. 1b suggested that the DT and ETA toxins
trafficked normally to the cytosol in CHO PR328, it was also
important to consider the alternative hypothesis that the ADP-
ribosylation seen in Fig. 1b was due to artifactual modification of
eEF-2 occurring after lysis of the cells. The RIPA buffer used for
the cell lysis is known to rupture all intracellular vesicles and it
does not contain inhibitors that would prevent ADP-ribosylation
catalyzed by toxin that was trapped in and only released from
vesicular compartments upon cell lysis. To examine this
hypothesis, cells were exposed to PA + FP59 for 1 h and then
incubated without toxin for additional periods of either 3 or 8 h.
After these times, cell lysates were prepared and the presence of
any remaining non-ribosylated eEF-2 was detected by addition of
biotin-NAD along with additional DT. If the FP59 trafficked
normally to the cytosol and ADP-ribosylated the eEF-2, then
unmodified eEF-2 would no longer be available for in vitro ADP-
ribosylation. If in contrast, the FP59 was trapped in vesicular
compartments and degraded over time, then it would produce
more biotin-ADP-ribose-eEF-2 at early than late times. The
former result was observed (Fig. 2a), since only a trace of ADP-
ribosylation was found, and this decreased with time of toxin
treatment of the cells. This shows that the modification of eEF-2
occurred prior to preparation of the lysates and was not artifactual.
Figure 2. Toxin internalization in CHO PR328 cells. (A) Cells were treated with PA and FP59 (1 mg/ml each) for 1 h. Then toxin was replaced
with fresh media after three washes with fresh medium, and incubated an additional 3 h or 8 h. At the end of desired incubation, cell lysates were
prepared and tested for DT-induced ADP-ribosylation in vitro using biotin-NAD. Equal amounts of protein were then separated by SDS-PAGE followed
by western blotting with streptavidin conjugated to Alexa Fluor dye and membrane was scanned on an Odyssey Infrared Imager. Left panel shows
the control cells that did not receive treatment with PA + FP59. Middle panel shows the data with cells treated with PA + FP59 for 4 h (1 h treatment
+ additional 3 h) while right panel is for cells treated with PA + FP59 for 9 h (1 h treatment + additional 8 h). – and + denote the absence or presence
of DT during the in vitro ADP-ribosylation reaction. Arrow indicates the biotin-ADP-ribose-eEF-2. (B) Cells were treated with PA and LFnBLA (1 mg/ml
each) for 1 h. Thereafter, 1.5 mM CCF2/AM was added to the cells for 1 h at room temperature. The CCF2/AM remaining in the medium was removed
by washing and cells were incubated an additional 1 h at room temperature to allow for CCF2/AM hydrolysis. The cells were then photographed with
a fluorescence microscope using an excitation wavelength of 405 nm and emission filters of 530 nm (green light) and 460 nm (blue light). Beta-
lactamase activity in treated cells is demonstrated by the blue fluorescence while control cells show green fluorescence.
doi:10.1371/journal.pone.0009078.g002
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eEF-2 in the ‘‘no toxin’’ controls (from Fig. 2a left panel) using
Odyssey software. The background corrected intensities of ADP-
ribosylated eEF-2 were 7519 and 4102 units for CHO WTP4 and
CHO PR328 cells, respectively, indicating ,50% less ADP-
ribosylated eEF-2 in CHO PR328 cells than in parental cells.
Intensities of bands obtained by western blotting with eEF-2
antibodies were nearly the same for both cells (data not shown).
To directly examine the internalization process, LFnBLA was
used to visualize the uptake in CHO PR328 cells. LFnBLA is a
fusion protein of LF amino acids 1-254 and b-lactamase. When
used in combination with PA, this fusion protein is translocated to
the cytosol of mammalian cells, where it’s catalytic activity can be
visualized using a fluorescent substrate, CCF2/AM [20,21]. This
membrane permeable substrate becomes both trapped in cells and
susceptible to cleavage by b-lactamase due to removal of the
acetoxy groups by cytosolic esterases. An intact molecule of
CCF2/AM emits at 520 nm (green light) when excited at 409 nm,
as a result of an intramolecular fluorescence resonance energy
transfer (FRET) between 7-hydroxycoumarin and fluorescein.
Hydrolysis of CCF2/AM by b-lactamase liberates the acceptor
fluorescein and leads to fluorescence at 447 nm (blue light) by the
donor coumarin. Thus, cells in which the LFnBLA fusion protein
reaches the cytosol show a shift of the initial green fluorescence to
blue. To determine whether LFnBLA (and by inference LF and
FP59) is internalized in CHO PR328, cells were incubated with
2 mg/ml each of PA and LFnBLA for 2 h, washed, loaded with
substrate for 2 h, and then imaged (Fig. 2b). Successful delivery of
LFnBLA into CHO PR328 and CHO WTP4 cells was evident by
the bright blue fluorescence of treated but not control cells. Several
other studies using PA mutants and inhibitors to provide
additional evidence about the normal uptake of toxin in CHO
PR328 cells have been included in supplementary materials (File
S1, Fig. S1 and Fig. S2).
Genotyping of eEF-2 Alleles
As described above, biochemical characterization of CHO
PR328 cells ruled out the presence of defects in toxin binding,
internalization, and trafficking. Instead, the data demonstrated
that toxin was internalized in CHO PR328 cells and successfully
ADP-ribosylated the eEF-2. In reviewing the available literature,
we recognized that previous reports had identified mutated eEF-2
variants which lack diphthamide but retain some degree of normal
function in translation. One such mutation, Gly717Arg, has been
observed in several previous studies [22–24] and has therefore
been considered an apparent mutational ‘‘hot spot’’. The nearby
His715 in this mutated eEF-2 cannot be modified to diphthamide,
apparently due to a structural perturbation that prevents
recognition by the diphthamide biosynthesis enzymes. Several
other reported, but less frequent, mutations in this region that
block diphthamide synthesis include Gly719Arg, Ile714Asn, and
Ser584Gly. Most of these residues are located in the strictly
conserved region around the diphthamide site in eEF-2 (Fig. S3). It
seemed reasonable to consider that CHO PR328 cells might be
heterozygous for one of these mutations, which could lead to the
observed dominant toxin-resistance phenotype.
A Gly717Arg mutation can result from a single bp change of G
to A at the first base of codon717 in the eEF-2 gene. Conveniently,
this change creates a diagnostic MboII restriction site [24]. To
determine whether CHO PR328 cells have this mutation, we
performed RT-PCR and restriction digestion with MboII. Fig. 3a
shows the schematic representation of the possible eEF-2 alleles.
As shown, there are two MboII restriction sites at bp 546 and 573
in the 796-bp amplified fragment from wild type eEF-2 cDNA. If
present, the mutation introduces an additional site at position 379
in the mutant eEF-2 gene. Upon restriction digestion with MboII,
homozygous wild type alleles will yield 3 fragments of 27, 223 and
546 bp, while homozygous mutant alleles will give 4 fragments of
27, 167, 223 & 379 bp, and, finally, heterozygous alleles should
give all 5 fragments of 27, 167, 223, 379 & 546 bp. Genotyping of
the eEF-2 gene in this way revealed that CHO PR328 cells are
indeed heterozygous for this eEF-2 mutation (Fig. 3b). The
heterozygous nature of the eEF-2 alleles and the presence of the G
to A transition in CHO PR328 cells were further confirmed by
sequencing of the RT-PCR product(s) (Fig. 3c). Thus, the ADP-
ribosylation observed in the cells occurs on the wild type eEF-2
protein, thereby inactivating it, while the mutant eEF-2 remains
active and is sufficient to support protein synthesis. This finding is
consistent with previous reports that cells can survive if they have
translation rates as low as 20–30% of normal [22,24].
Effect of Toxin Exposure on Subsequent Responses to
Toxin
We further characterized CHO PR328 cells to analyze their
growth characteristics. In the presence of toxin, CHO PR328 cells
exhibited reduced growth as confirmed by phase-contrast
microscopy (data not shown). To examine the long-term response
of the cells, they were treated with PA plus FP59 for 48 h (as in
Fig. 1) and then grown further in fresh toxin-free medium. After
an additional two days of growth, these cells were assayed for their
sensitivity to eEF-2 ADP-ribosylating toxins (Fig. 4). The cells
showed 100% resistance to toxin, and thus behaved as if they did
not receive a second toxin treatment (Fig. 4). This argues that all
the wild type eEF-2 in these cells remain fully ADP-ribosylated due
either to the earlier treatment with toxin or to the survival of
catalytically active toxin in the cytosol. Thus, the newly added
toxin could have no further impact on the growth or survival of the
cells. When this experiment was extended to longer time intervals,
the resistance of the toxin-treated cells returned to the original
50% level after one week of growth (data not shown, similar to
Fig. 1), indicating that the toxin had decayed and that the ADP-
ribosylated wild type eEF-2 is eventually replaced by newly
synthesized wild type eEF-2.
Discussion
We previously used retroviral insertional mutagenesis to identify
genes involved in the action of anthrax toxin on cells [18,19]. In
one approach, CHO cells transfected with the receptor for avian
leukosis virus (ALV) were treated with an ALV vector and then
selected with PA plus the fusion protein FP59. One group of the
resulting toxin-resistant mutants lacked functional PA receptors
and showed resistance to PA plus FP59, but retained sensitivity to
DT and ETA (e.g., CHO PR230; [19]). Another group of mutants
showed resistance not only to PA plus FP59 but also to DT and
ETA, suggesting that the cells were altered in genes affecting eEF-
2, the target shared by these three toxins. One mutant cell line
from the latter group was found to have a disruption of a small
gene, DESR1 (later renamed Dph3), that is required for the
biosynthesis of diphthamide [10,18]. The CHO PR328 cells
discussed in this report were in the second group of mutant cells
which showed less sensitivity to the ADP-ribosylating toxins. These
mutant cells are different from earlier reported mutant cells as the
eEF-2 of these cells are sensitive to toxin-induced ADP-ribosyla-
tion while the cells show reduced sensitivity. We performed several
studies (FP59-induced ADP-ribosylation and effect of well
established mutants and inhibitors; imaging of cells after delivery
of fusion protein LFnBLA, and activity of anthrax lethal toxin) to
eEF-2 Lacking Diphthamide
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results indicated that the cells had normal toxin binding and
internalization (see supporting information, File S1).
Southern blotting showed that CHO PR328 cells did not
contain any retroviral insertions (data not shown) indicating the
presence of a spontaneous mutation in these cells. Given the large
size of the mammalian genome, any random forward mutational
selection must examine a very large number of cells to find the rare
mutation that causes the desired phenotype. Applying a pheno-
typic selection to such a large population will inevitably lead to
simultaneous selection of spontaneous mutations, which is clearly
what occurred in the present case.
Several previous reports described structural gene mutations in
eEF-2 which block the post-translational modification of His715 to
diphthamide without seriously decreasing the ability of eEF-2 to
participate in protein synthesis [22–24]. One of these mutations,
Gly717Arg, was described in prior reports [22–24]. Restriction
analysis confirmed the presence of an Arg717 codon in one of the
alleles of eEF-2 in CHO PR328 cells. Sequencing the gene further
confirmed that CHO PR328 cells are heterozygous, with one
allele being wild type and the other having the Arg717 codon. This
residue is in close proximity to the His715 that is normally
modified to diphthamide. Substitution of this residue with Arg
abolishes the modification of His715 to diphthamide, making this
Figure3. Genotyping of eEF-2from CHO WTP4 and CHO PR328cells. (A) Schematic representation for the presenceof MboII restrictionsites in
heterozygous alleles in a 796-bp eEF-2 PCR product. Double lines indicate the two alleles of eEF-2 while vertical small lines show the sites for MboII
restriction enzymes. There are two sites in wild type eEF-2 (bottom line) while the G to A transition introduces one more site in the mutant allele (top
line).(B) RNA was extractedfrom CHO WTP4 andCHO PR328cells using TRIzolreagent. RT-PCR was performed andamplifiedproduct wasdigested with
MboII restriction enzyme. Digested DNA samples along with controls were then separated on 1% agarose gel and visualized using UV gel
documentationsystem.M:1 kbDNAladder;Lane1:CHO WTP4 control; Lane 2:CHOWTP4 digested;Lane 3:CHOPR328control;andLane4:CHO PR328
digested. Presence of 5 bands is evidentfor CHO PR328 cellswhile CHO WTP4 cellsshows only 3 bands on DNAgel. (C) RT-PCR samples obtained for the
analysis of panel B were sequenced. Sequence shown is of complementary strand as reverse primer was used to sequence the region. Zoomed image
shows thepresenceof twopeaks (C& T) ineEF-2 ofCHOPR328cells as opposedto onlyone peak (C)inCHOWTP4 cells in the same regionrevealingthe
presence of G & A bases in eEF-2 of CHO PR328 at this location. As expected, CHO WTP4 eEF-2 had only G base at same location.
doi:10.1371/journal.pone.0009078.g003
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has no detectable impact on protein synthesis in cells. Thus, the
mutant allele allows the survival of CHO PR328 cells in the
presence of toxin, as only 50% of the cellular eEF-2 is inactivated
by the toxin while the other 50% eEF-2 remains functional due to,
and in spite of, the absence of diphthamide. The survival and
continued proliferation of these cells suggests that the ADP-
ribosylated and inactive eEF-2 does not strongly compete with
mutant (Arg717) eEF-2 for the protein synthesis machinery.
However, some inhibitory effect cannot be ruled out, because cells
can survive even at 20–30% of the normal translation rate [24].
The amino acid sequence of eEF-2 around His715 and the
presence of the diphthamide side chain are both conserved in all
eukaryotes (Fig. S3). This probably reflects the multiple functional
roles played by this region – recognition by the enzymes that
construct the diphthamide side chain, the apparent gain in normal
function conferred by diphthamide [25], and participation by the
proximal regions (even in the absence of diphthamide) in the
elongation step on ribosomes. These multiple structural require-
ments limit the opportunities for creation of mutations that lack
diphthamide while retaining function in protein synthesis. Thus, it
is not surprising that only a few such mutations have been
reported. The mutations other than those presented here which
can provide such resistance are Gly719Arg, Ile714Asn, and
Ser584Gly, but these appear to be less frequent. Most of these
mutations (except Ser584) lie in the highly conserved diphthamide
loop. In fact, Ser584 is located close to His715 in the three-
dimensional structure of EF-2 of other species [24], suggesting an
important role of this residue. The lower frequency of selection of
other mutants may reflect a decreased ability of other eEF-2
variants to support protein synthesis, thereby causing a greater
growth defect, and decreasing the chance that a colony will grow
big enough to be detected and picked. We speculate that the
Gly717Arg mutation is favored because it provides a positive
charge that mimics that of diphthamide. In this view, substitution
of Gly717 to Arg prevents the diphthamide biosynthesis but at the
same time provides a ‘‘replacement’’ positive charge in this region
which is sufficient to confer some degree of functionality. This
hypothesis about the role of positive charge in the region needs
further anylsis. If diphthamide-deficient mutant eEF-2 proteins
function perfectly well, it then becomes difficult to understand the
retention of the diphthamide modification in such a diverse set of
species, which argues strongly for its essentiality.
Materials and Methods
Materials
PA, LF, FP59, DT, ETA, and PA mutant proteins were
produced in our laboratory as described previously [26–28].
LFnBLA, consisting of the N-terminal region of LF (LFn) and b-
lactamase (BLA), was produced as previously described [20]. Anti-
eEF-2 antibodies specific to the carboxy-terminus of eEF-2 of
human origin were purchased from Upstate (Now Millipore,
Billerica, MA) and Santa Cruz Biotechnology (Santa Cruz, CA),
respectively.
Cell Culture and Cytotoxicity Assays
Cells were grown in a-minimal essential medium (MEM)
supplemented with 8% fetal bovine serum, 25 mM HEPES,
2 mM glutamine and 50 mg/ml gentamicin (all obtained from
Invitrogen) at 37uC in 5% CO2. For cytotoxicity assays, cells were
sub-cultured in 96-well plates one day prior to experiments as
described previously [9]. Cells were treated with various
concentrations of toxins for 48 h and cell viability was measured
by adding 0.5 mg/ml MTT (3-[4,5-dimethylthiazol-2,5-diphenyl-
tetrazolium bromide) in a-MEM. Following a 45-min incubation,
the MTT medium was removed and cells were dissolved with
100 ml/well of 0.5% SDS, 25 mM HCl in 90% isopropanol. A
plate reader was used to read the A570 values for each well, and
percent viability was calculated relative to wells that were not
treated with toxin.
Toxin-induced ADP-ribosylation of eEF-2
The detection of toxin-induced ADP-ribosylation of eEF-2 in
intact cells was performed as previously described [18]. Briefly,
cells were treated with toxin and cell lysates were prepared using
RIPA lysis buffer (1% Nonidet P40, 0.5% sodium deoxycholate
and 0.1% SDS in PBS) containing Complete protease inhibitor
cocktail (Roche Diagnostics, Indianapolis, IN). Protein concentra-
tions were estimated using BCA reagent and equal amount of
proteins were subjected to native PAGE followed by western
blotting. Membranes were probed with anti-eEF-2 antibodies.
Alternatively, to assess ADP-ribosylation of eEF-2 in extracts of
cells previously treated with toxin, the eEF-2 that was not already
modified was quantitated by reaction with biotinylated NAD [9]. In
brief, cells were lysed in RIPA buffer containing protease inhibitors
and cell lysate (50 mg) was incubated with 100 ng of DT in ADP-
Figure 4. Effect of toxin exposure on CHO PR328 cells for subsequent cytotoxicity to toxin. CHO PR328 cells were treated with PA + FP59
(1 mg/ml) for 48 h and then placed into fresh medium lacking toxin. Cells grown for an additional two days are designated CHO PR328-T. In toxicity
assays, cells were treated with different concentrations of FP59 at a fixed concentration of PA (500 ng/ml) for 48 h and then MTT assay was
performed to measure cell viability. CHO WTP4 cells were included as control in the experiment.
doi:10.1371/journal.pone.0009078.g004
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PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9078ribosylation buffer (20 mM Tris-HCl, pH 7.4; 1 mM EDTA;
50 mM DTT) with 5 mM 6-Biotin-17-NAD (Trevigen) for 30 min
at25uC.SamplesweresubjectedtoSDS-PAGEfollowedbywestern
blotting with streptavidin-IR conjugate (Rockland Immunochem-
icals, Gilbertsville, PA) to detect biotin-ADP-ribose-eEF-2.
Imaging Beta-Lactamase Activity in Cells
Activity of beta-lactamase was measured using the fluorogenic
substrate, CCF2/AM (Invitrogen) as described previously [20,21].
Cells were sub-cultured in 6-well plates one day prior to treatment
with toxin. Cells were treated with PA and LFnBLA (2 mg/ml each)
for 1 h at 37uC and fresh media replaced the toxin medium. CCF2/
AM substrate was prepared as a 6X solution by mixing three
components of the kit as mentioned in the manufacturer’s
instructions. For loading the cells, substrate was diluted directly in
the medium for a final concentration of 1.5 mM and incubated for
60 min at room temperature and then replaced with fresh medium.
Cells were incubated for an additional 1 h at room temperature to
allow FRET disruption. Cells were then visualized and photographed
using a Zeiss Axioplan inverted microscope with Zeiss Axiovision
software (Carl Zeiss, Jena, Germany). For acquisition of blue
fluorescence, excitation filter HQ405/20 nm bandpass, dichroic
425DCXR, and emitter filter HQ460/40 nm bandpass were used.
For green fluorescence, HQ405/20 nm bandpass, dichroic
425DCXR, and emitter filter HQ530/30 nm bandpass were used.
All filters and dichroic mirrors were purchased from Chroma
Technology (Rockingham, VT). All images were acquired using the
identical settings.
Genotyping of eEF-2 Alleles
RNA was extracted using TRIZol reagent (Invitrogen) as per
the guidelines. cDNA was synthesized using Superscript (Ambion,
now part of Applied Biosystems, Austin, TX) according to the
instructions. RT-PCR was carried out to amplify the eEF-2
cDNA. Forward primer 59-GTCGCCCAACAAGCACAACCG-
39 and reverse primer 59-GGGACTGT GGATCCCTAATGAT-
GATGATGATGATGCAGTTTGTCCAGGAAGTTGTCCAG-
T-39 were used to amplify a 796-bp product of eEF-2 cDNA. An
annealing temperature used for PCR was 61uC. The RT-PCR
product was purified with PureLink PCR purification kit (Invitro-
gen, Carlsbad, CA) and digested with MboII restriction enzyme for
2 h. Digested DNA samples were subjected to agarose gel
electrophoresis to identify the size of DNA fragments.
Supporting Information
File S1 Supplementary materials text.
Found at: doi:10.1371/journal.pone.0009078.s001 (0.06 MB
DOC)
Figure S1 Effect of PA mutants and inhibitors on toxin-induced
ADP-ribosylation of eEF-2 in CHO WTP4 and CHO PR328
cells. (A) Cells were treated with FP59 in combination with PA or
PA mutants (each 100 ng/ml) for 1 h and then replaced with fresh
media. For inhibitor studies, cells were treated with PA + FP59 in
the presence of inhibitors (dominant negative mutant of PA,
ammonium chloride, or bafilomycin A1) for 1 h and then fresh
media replaced toxin. For inhibitors studies with ammonium
chloride and bafilomycin, cells were pre-incubated with the
respective inhibitors and same inhibitor concentration was
maintained during and post-toxin treatment. After a further
incubation of 3 h, cell lysates were prepared and equal amounts of
protein were loaded on native PAGE followed by western blotting.
The membrane was probed with antibody against the carboxy-
terminus of eEF-2 of human origin and scanned on Infrared
Imager. (B) Toxin-induced ADP-ribosylation in cytosol of CHO
PR328 cells. Cells were incubated with FP59 in combination with
PA or PA mutant (1 mg/ml each) for 45 min and then fresh media
replaced the toxin medium. After an additional incubation of
2.5 h, cytosol was prepared from cells using a hypotonic solution
of sucrose. Equal amounts of protein were separated on native
PAGE followed by blotting with antibody against the carboxy-
terminus of eEF-2 of human origin. Lower panel shows the SDS-
PAGE and western blot of same samples and same antibodies to
show the equal amount of proteins.
Found at: doi:10.1371/journal.pone.0009078.s002 (0.60 MB PPT)
Figure S2 Anthrax lethal toxin-induced cleavage of MEK1 in
CHO WTP4 and CHO PR328 cells. Cells were treated with PA +
LF (1 mg/ml each) for indicated time periods and then lysates were
prepared using RIPA buffer having protease inhibitors. Equal
amounts of samples were subjected to SDS-PAGE and western
blotting with anti-MEK1-NT antibodies.
Found at: doi:10.1371/journal.pone.0009078.s003 (0.23 MB PPT)
Figure S3 Sequence analysis of eEF-2. Protein sequences for
eEF-2 from different organisms were obtained from available
databases and aligned using clustal W software. Accession no. for
eEF-2 sequences are- Cricetulus griseus (GenBank: AAB60497.1);
Rattus norvegicus (NCBI Reference Sequence: NP_058941.1);
Homo sapiens (GenBank- CAA35829.1); Drosophila melanogaster
(Swiss-Prot: P13060.4); Saccharomyces cerevisiae (NCBI ref. no.:
NP_014776.1) and Methanococcus vannielii (Swiss-Prot:
P09604.2). Arrow ( ) points to the His715 residue that is modified
to make the diphthamide residue. ‘‘*’’ below the multiple
alignment shows the strictly conserved amino acids between
different organisms. ‘‘ Q’’ denote the reported mutation sites
(residues no. Ile714, Gly717 and Gly719 in mammalian eEF-2).
As is evident, the region around the diphthamide site (diphthamide
loop; residues 709–719 in mammalian eEF-2) is quite conserved
among various organisms and most of the mutations reported lie
within this loop. Only one other mutation (Ser584 in mammalian
eEF-2; not shown here) far from this region is reported, but based
on the three-dimensional structure of homologous proteins this
residue is also located very close to the diphthamide region.
Found at: doi:10.1371/journal.pone.0009078.s004 (0.12 MB PPT)
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